Table 1.
Demographics and clinical evaluations of the 12 Parkinson's disease patients at baseline, 16-h and after 24-h LCIG infusion
| UPDRS | UPDRS | UPDRS | UPDRS | HY | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt | PD-AOO | Age at initiation 16-LCIG | Age at initiation 24-LCIG | Indication | Oral medications | Part 3 | Part 4 | 4.1 | 4.2 | Change in UPDRS 4.1 after 24-h LCIG | Change in UPDRS 4.2 After 24-h LCIG | Outcome | Complications | |||||||||||
| B | 16-h LCIG | 24-h LCIG | B | 16-h LCIG | 24-h LCIG | B | 16-h LCIG | 24-h LCIG | B | 16-h LCIG | 24-h LCIG | B | 16-h LCIG | 24-h LCIG | ||||||||||
| 1a | 52 | 62 | 65 | Self-initiated | None | NA | 9 | 9 | 11 | 8 | 2 | 2 | 2 | 1 | 3 | 3 | 0 | 2 | 2 | 2 | −1 | −1 | Reduction of dyskinesias | 4, 5 |
| 2a | 30 | 61 | 63 | FOG | Amantadine 300 mg/day Pramipexol 1 mg nocte | 19 | 13 | 13 | 12 | 8 | 6 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | −1 | −1 | Reduction of dyskinesias | 2, 4, 5, 6 |
| 3 | 50 | 63 | 64 | Dysk | LC 100/25 mg nocte/ Amantadine 200 mg/day | 35 | 29 | 24 | 13 | 9 | 5 | 4 | 4 | 1 | 3 | 2 | 1 | 2 | 2 | 2 | −3 | −1 | Reduction of dyskinesias | None |
| 4 | 44 | 56 | 57 | Dysk | None | 15 | 15 | 11 | 12 | 7 | 4 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 0 | −3 | Reduction of dyskinesias | 4, 5 |
| 5 | 42 | 68 | 71 | Dysk | LC CR 200/50 mg nocte | 26 | 28 | 31 | 10 | 11 | 6 | 3 | 3 | 2 | 3 | 4 | 2 | 2 | 2 | 2 | −1 | −2 | Reduction of dyskinesias | 1, 2, 4, 5 |
| 6 | 59 | 69 | 70 | Nocturnal akinesia and daytime Dysk | None | 49 | 10 | 10 | 9 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | No improvement of dyskinesias | 2, 4 |
| 7a | 66 | 81 | 81 | FOG | None | 29 | 37 | 23 | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | Improvement of FOG- No dyskinesias | 4 |
| 8 | 65 | 78 | 80 | Dysk | LC CR 200/50 mg nocte | 31 | 17 | 18 | 11 | 9 | 6 | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | −1 | −1 | Reduction of dyskinesias | 4 |
| 9a | 61 | n/a | 81 | FOG and Dysk | Pramipexol 1 mg nocte | 52 | 65 | 40 | 9 | 8 | 6 | 3 | 3 | 1 | 0 | 0 | 0 | 3 | 3 | 3 | −2 | 0 | Reduction of dyskinesias | 1, 4 |
| 10 | 39 | n/a | 67 | FOG and Dysk | None | 46 | 42 | 44 | 13 | 11 | 12 | 2 | 2 | 1 | 2 | 2 | 1 | 3 | 2 | 2 | −1 | −1 | Reduction of dyskinesias | 3, 4, 5, 6 |
| 11 | 40 | 50 | 51 | Nocturnal akinesia and daytime Dysk | None | 17 | 13 | 7 | 10 | 5 | 7 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | −2 | 0 | Reduction of dyskinesias | 5 |
| 12 (treatment 1) | 63 | n/a | 74 | FOG | None | 24 | 18 | 18 | 8 | 6 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | No improvement of dyskinesias/ FOG improved but returned to 16-h due to hallucinations | 1, 4, 5 |
| 12 (treatment 2) | 74 | 77 | FOG and Dysk | None | 22 | 23 | 24 | 11 | 11 | 11 | 2 | 2 | 2 | 4 | 4 | 4 | 3 | 3 | 3 | 0 | 0 | No improvement of dyskinesias/ FOG improved | 1 |
PD-AOO Parkinson’s disease age of onset, B baseline, UPDRS Unified Parkinson’s Disease Rating scale, HY Hoehn & Yahr, Dysk dyskinesia, FOG freezing of gait, LC levodopa/carbidopa, LC CR levodopa/carbidopa controlled release, n/a not applicable
aPatients previously reported: Ref. 4
1-Worsening of previous nocturnal hallucinations; 2-Non-disabling neuropathy with 16-h LCIG; 3-Asymptomatic de novo neuropathy ; 4-Vitamin B6 deficiency ; 5-Vitamin B 12 deficiency; 6-Hyperhomocysteinaemia